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Neuroﬁlament light (NfL) protein in blood plasma has been proposed as a prognostic bio-
marker of neurodegeneration in a number of conditions, including Huntington disease (HD).
This study investigates the regional distribution of NfL-associated neural pathology in HD gene
expansion carriers.
Methods
We examined associations between NfL measured in plasma and regionally speciﬁc atrophy in
cross-sectional (n = 198) and longitudinal (n = 177) data in HD gene expansion carriers from
the international multisite TRACK-HD study. Using voxel-based morphometry, we measured
associations between baseline NfL levels and both baseline gray matter and white matter
volume; and longitudinal change in gray matter and white matter over the subsequent 3 years in
HD gene expansion carriers.
Results
After controlling for demographics, associations between increased NfL levels and reduced
brain volume were seen in cortical and subcortical gray matter and within the white matter.
After also controlling for known predictors of disease progression (age and CAG repeat
length), associations were limited to the caudate and putamen. Longitudinally, NfL predicted
subsequent occipital gray matter atrophy and widespread white matter reduction, both before
and after correction for other predictors of disease progression.
Conclusions
These ﬁndings highlight the value of NfL as a dynamic marker of brain atrophy and, more
generally, provide further evidence of the strong association between plasma NfL level, a can-
didate blood biomarker, and pathologic neuronal change.
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The identiﬁcation of sensitive biomarkers of disease pro-
gression could help in the development of successful treat-
ments for neurodegenerative conditions. Blood biomarkers
are particularly appealing as they provide a quick, noninvasive,
objective, and reproducible way of quantifying markers
of disease progression. Neuroﬁlament light (NfL) has been
recognized as a CSF biomarker of neuronal damage for
a number of years, but recent advances in ultrasensitive
immunoassays have enabled quantiﬁcation of NfL from blood
samples.1 Recently, NfL was proposed as a candidate prog-
nostic blood biomarker of Huntington disease (HD) onset
and progression.2 Baseline NfL was retrospectively quantiﬁed
in plasma using the well-characterized TRACK-HD cohort.3–6
NfL was increased in HD gene expansion carriers when
compared to controls, with NfL levels reﬂecting baseline
motor and cognitive deﬁcits, as well as reduced global and
regional brain volume. Baseline NfL also predicted disease
progression in these 3 domains over the following 3 years.
This previous study highlights the potential importance of
NfL as a promising dynamic blood biomarker of not only
current disease status and onset, but also ongoing progression
in HD. However, global or region-of-interest measures pro-
vide limited insight into the regional distribution of NfL-
associated pathology due to the HD gene mutation. Here, we
use both cross-sectional and longitudinal voxel-based mor-
phometry (VBM) in the same TRACK-HD cohort to map the




Participants were recruited as part of the multisite longitu-
dinal TRACK-HD study, which included 120 participants
with premanifest HD (preHD) and 123 participants with
manifest HD.2 Participants were recruited in 2008 from
hospital clinics at 4 sites based in Leiden, London, Paris, and
Vancouver and were classiﬁed as having premanifest or mani-
fest HD at baseline depending on their score on the Uniﬁed
Huntington’s Disease Rating Scale (UHDRS) Total Motor
Score.7 A score of ≤5 meant that a participant was catego-
rized as preHD, and participants with a Total Motor Score
>5 combined with a UHDRS Total Functional Capacity
score >7 were classed as early manifest HD. Disease Burden
Score,7 an approximate marker of disease load, and 5-year
probability of onset,8 an approximate prediction of disease
onset, were calculated for this cohort. Participants un-
derwent a series of assessments and returned yearly until
2011. Sample size was calculated before the TRACK-HD
baseline visit and was aimed at detecting signiﬁcant longi-
tudinal change over 2 years in diﬀerent variables.3 Full
study and recruitment information has been documented
previously.3
Standard protocol approvals, registrations,
and patient consents
Local ethical approval was given for the study and all partic-
ipants gave their written informed consent according to the
Declaration of Helsinki.
Imaging acquisition and processing
Three-tesla MRI scans were collected at all 4 sites using
a standardized T1-weighted acquisition developed for this
study.2
Scans underwent rigorous quality control, with meta-data
checks and visual quality-control steps performed to ensure
that acquisition parameters were correct and to exclude
scans with motion and other artifacts. All scans that passed
quality control were then processed using SPM 12 (http://
www.ﬁl.ion.ucl.ac.uk/spm/) withMATLAB version R2012B
(https://in.mathworks.com). Baseline volumes were sepa-
rated into diﬀerent tissue classes (gray matter [GM], white
matter [WM], and CSF) using the Segment procedure.
A group template was created using Diﬀeomorphic Ana-
tomical Registration Through Exponentiated Lie Algebra10
(DARTEL), and the WM and GM tissue classes were then
warped to the DARTEL template. These images were
modulated and smoothed to account for any volume changes
that occurred during normalization. A 4-mm kernel at full-
width half maximum was used for smoothing. All images
were visually examined to check segmentation and normal-
ization performance.
Longitudinal VBM was performed as described previously.5,11
Within-subject longitudinal change was ﬁrst measured
using a nonlinear ﬂuid registration technique within in-
house MIDAS software.12 Voxel-compression maps were
generated for each participant from baseline to 3-year follow-
up.11,13 These voxel-compression maps were then spatially
mapped onto the DARTEL template and then convolved
with the participant-speciﬁc baseline GM and WM maps to
generate voxel-level, within-subject change for each tissue
type.11
Total intracranial volume was measured via the MIDAS
software12 using a semiautomated procedure as previously
described.14 All image analyses were performed blinded to
participant group to avoid potential sources of bias.
Glossary
DARTEL =Diﬀeomorphic Anatomical Registration Through Exponentiated Lie Algebra;GM = gray matter;HD =Huntington
disease;NfL = neuroﬁlament light; preHD = premanifest Huntington disease;UHDRS = Uniﬁed Huntington’s Disease Rating
Scale; VBM = voxel-based morphometry; WM = white matter.
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NfL quantification
NfL was quantiﬁed in plasma samples using an ultrasensitive
single-molecule array method as previously described.6 All
samples were analyzed in one round of experiments using one
batch of reagents. All NfL values were within the linear ranges
of the assays, and intra-assay coeﬃcients of variation were
below 10%. NfL quantiﬁcation was performed blinded to
group to avoid potential sources of bias.
Statistical analysis
Associations between NfL and (1) cross-sectional GM or
WM volumes, and (2) longitudinal GM and WM change
were examined using linear regression models within SPM
12. Age, sex, study site, and total intracranial volume were
initially controlled for in the model, to permit identiﬁcation
of regions where atrophy was associated with plasma NfL.
To identify regions where NfL independently predicted at-
rophy, after adjustment for known predictors of HD pro-
gression, the analysis was then repeated with CAG repeat
length and age–CAG interaction as terms. These terms are
known predictors of HD disease onset and stage, and thus by
controlling for these factors, we can better understand the
independent inﬂuence of NfL on GM and WM.15 Explicit
binary masks for GM and WM were used in the analysis, as
described previously.16 All results were one-tailed and cor-
rected for multiple comparisons at p = 0.05 using family-wise
error.
Results
Of the 243 gene expansion carriers recruited in
TRACK-HD, 201 had plasma samples collected at base-
line (2008) from which NfL could be measured, and 198
also had structural imaging that passed quality control at
baseline. Of these participants, 176 had both plasma
samples and structural MRI scans at the 3-year follow-up
(2011), with an additional participant who had a struc-
tural MRI scan but no plasma. Although retention was
high for the study, the most common reason for drop-out
at the 2011 time point was worsening of symptoms.
Detailed information on retention was discussed pre-
viously.3 Demographic information is provided in the
table.
Baseline NfL: Relationship to GM and WM
volume at baseline
Before adjusting for CAG repeat length and the CAG × age
interaction, there were signiﬁcant associations between
higher baseline plasma NfL and lower subcortical and cor-
tical volume of the GM, especially within the striatum and
occipital lobe (ﬁgure 1A). Signiﬁcant associations were also
seen with reduced WM surrounding the striatum and within
the corpus callosum (ﬁgure 1B). Following adjustment for
CAG repeat length and the interaction between age and
CAG repeat length, higher baseline NfL was signiﬁcantly
associated with reduced volume in the caudate and putamen
bilaterally (ﬁgure 2). There were no associations between
NfL and WM volume that survived correction for multiple
comparisons.
Baseline NfL: Relationship to longitudinal GM
and WM volume change
Higher baseline levels of plasma NfL were positively associated
with subsequent longitudinal volume loss bilaterally in the
caudate, putamen, and occipital cortex (ﬁgure 3A). Higher
baseline NfL was also positively associated with subsequent
widespread volume reduction within the WM, most
Table Demographic information for all participants at baseline
Combined preHD HD
No. 198 104 94
Age, y 44.59 (9.96); 18.63–64.13 40.98 (8.67); 18.63–64.13 48.59 (9.81); 22.76–64.11
Sex, M/F 107/91 56/48 51/43
CAG 43.32 (2.75); 39.00–59.00 43.04 (2.32); 39.00–50.00 43.64 (3.13); 39.00–59.00
TMS 12.12 (12.57); 0.00–47.00 2.53 (1.68); 0.00–8.00 22.72 (10.72); 5.00–47.00
TFC 12.03 (1.63); 7.00–13.00 12.84 (0.59); 9.00–13.00 11.13 (1.91); 7.00–13.00
DBS 330.30 (74.87); 156.19–566.46 292.63 (47.48); 171.00–408.90 371.98 (77.68); 156.19–566.46
Probability 5-y onseta 0.34 (0.19); 0.03–0.74 0.22 (0.12); 0.03–0.53 0.46 (0.16); 0.03–0.74
GM volume, % of TIV 45.42 (4.27); 32.41–56.07 47.57 (3.07); 37.42–56.07 43.04 (4.16); 32.41–51.63
WM volume, % of TIV 28.74 (2.12); 23.63–34.30 29.57 (1.91); 25.02–34.30 27.82 (1.95); 23.63–33.78
Abbreviations: CAG= length of genetic repeat; DBS =DiseaseBurdenScore9; GM=graymatter; HD =Huntington disease; preHD=premanifestHD; TFC = Total
Functional Capacity7; TIV = total intracranial volume; TMS = Total Motor Score; WM = white matter.
Values are mean (SD); range.
a Conditional probability of onset within 5 years.8
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signiﬁcantly in the corpus callosum (ﬁgure 3B). Figure 4A
shows that after controlling for CAG repeat length and the
interaction between age and CAG repeat length, NfL primarily
predicted subsequent GM reduction within the inferior oc-
cipital cortex and the lateral occipital cortex. Signiﬁcant asso-
ciations were also seen in small regions within the inferior
frontal gyrus and superior temporal gyrus. Finally, higher
baseline NfL again showed widespread associations with lon-
gitudinal WM volume reductions, even after adjusting for CAG
and the age × CAG interaction term (ﬁgure 4B).
Discussion
This study presents unbiased whole-brain results showing
voxel-wise region-speciﬁc associations between NfL levels
measured in plasma and both cross-sectional and longitudinal
MRI GM and WM volume in a pathologic group previously
shown to have raised NfL levels. One previous study in HD
found associations between the level of NfL in plasma and
MRI measures of cross-sectional brain volume and brain at-
rophy over the subsequent 3 years in a number of predeﬁned
Figure 1 Significant associations between baseline NfL and baseline GM and WM volume
Statistically significant negative associations between baseline NfL and (A) baseline GM volume and (B) baseline WM volume. All analyses were adjusted for
age, sex, study site, and total intracranial volume corrected at p < 0.05 family-wise error and are displayed on a study-specific template. GM = gray matter;
NfL = neurofilament light; WM = white matter.
Figure 2 Significant associations between baseline NfL and baseline GM volume after adjustment for CAG
Statistically significant negative associations between baseline NfL and baseline GM volume after additional adjustment for CAG repeat length and the
interaction between age and CAG repeat length. All analyses were adjusted for age, sex, study site and total intracranial volume corrected at p < 0.05 family-
wise error and are displayed on a study-specific template. GM = gray matter; NfL = neurofilament light.
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regions of interest using global values.6 Here, we build on this
previous work, using VBM to reveal the location and extent of
volumetric change in brain regions that are associated with
NfL levels in HD.
As expected, higher NfL in plasma was associated with lower
volume in regions known to be aﬀected in HD. After ad-
justment for CAG repeat length and its interaction with
age—known predictors of HD progression15—NfL remained
independently associated with reduced GM volume in the
caudate and putamen bilaterally, but there was no association
with cortical or WM volume at baseline. The caudate and
putamen are regions that undergo the earliest and most ex-
tensive atrophy in HD due to the predominance of medium
spiny neurons that are particularly vulnerable to the eﬀects of
mHTT.15 However, it appears that baseline NfL level does not
speciﬁcally relate to more widespread neuronal damage at
a given time point, beyond the overall general eﬀect of age and
CAG repeat length on neurodegeneration. That the caudate
and putamen were associated with NfL concentration after
age and CAG adjustment suggests that NfL is capable of
identifying individuals who, over the course of their life up to
the time of sampling, have experienced relatively larger or
smaller volume loss in these disease-linked brain regions.
It is of interest that there was a much stronger relationship
between baseline NfL levels and subsequent regional volume
loss over time, with these relationships remaining highly sig-
niﬁcant after adjusting for CAG repeat length and its in-
teraction with age. Higher baseline levels of NfL signiﬁcantly
predicted increased atrophy in cortical but not subcortical
regions of the GM over the following 3 years, which is con-
sistent with the previous study reporting stronger association
between baseline NfL and total GM than caudate atrophy.6
Our results extend this ﬁnding by providing further evidence
that, after controlling for overall age and CAG eﬀects, higher
NfL is predictive of HD gene expansion carriers who will
subsequently undergo greater GM atrophy extending beyond
the striatum. This study demonstrates that the most signiﬁ-
cant associations between NfL and subsequent neuronal
change are localized to the occipital lobe, one of the earliest
cortical regions thought to undergo atrophy in HD.2,17,18
While previous studies have found that the occipital lobe
appears to be an early region of neural change, neuropathol-
ogy studies have found that in more advanced cases of HD,
cortical atrophy is globally distributed.19 The signiﬁcant as-
sociation between higher NfL and subsequent atrophy sug-
gests that NfL is sensitive to some of the earliest cortical
atrophy in HD.
In addition to cortical GM atrophy, there was a strong re-
lationship between higher baseline NfL levels and widespread
atrophy within the WM. WM has been shown to undergo
change in both preHD and manifest HD,5 and is strongly
Figure 3 Significant associations between baseline NfL and change in GM and WM volume
Statistically significant negative associations between baseline NfL and longitudinal change in (A) GM volume and (B) WM volume. All analyses were adjusted
for age, sex, study site, and total intracranial volume, corrected at p < 0.05 family-wise error, and are displayed on a study-specific template. GM= graymatter;
NfL = neurofilament light; WM = white matter.
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related to disease progression.3 Our ﬁndings suggest that,
similarly to GM,NfL is predictive of subsequentWM atrophy.
These associations indicate that it in addition to its value as an
accessible indicator of global neurodegeneration, NfL may
have particular value as a marker of axonal degeneration—and
therefore potentially reversible neuropathology in regions
vulnerable to damage in HD.20,21
Whole-brain analyses using VBM have only been used to
examine the relationship between NfL—measured in CSF,
not plasma—and neuronal change in a neurologic illness
(frontotemporal dementia) in one previous study.22 However,
the current ﬁndings are the ﬁrst to show signiﬁcant associa-
tions between NfL in plasma across the whole brain in both
cross-sectional and longitudinal data. Even though plasma
NfL has been shown to increase longitudinally in HD, and the
associations of such longitudinal change may be of interest,6
our results suggest that a single baseline measurement of NfL
has the ability to identify gene expansion carriers who have
previously undergone disproportionate atrophy in the basal
ganglia, and those who are likely to go on to develop similarly
disproportionate atrophy in cortical and WM regions vul-
nerable to HD pathology. This corroborates previous ﬁnd-
ings6 and supports the hypothesis that NfL is a dynamic,
rapidly-assessed marker of ongoing neuronal damage. Pre-
vious reports from the TRACK-HD study demonstrated that
patients with the highest atrophy rates were those who
subsequently showed the greatest clinical decline.3 Here, we
demonstrate that the region-speciﬁc predictive power of NfL
extends beyond predeﬁned large volumes of interest. This
provides further evidence for the utility of NfL as a potential
eﬃcacy and disease progression biomarker in therapeutic in-
tervention trials.
We showed a highly signiﬁcant and widespread association
between plasma NfL and change in WM volume using VBM.
In the future, use of microstructural measures of WM de-
generation derived from diﬀusion imaging may allow a de-
tailed characterization of the relationship with NfL, providing
further mechanistic insights into the breakdown of brain
connectivity, which we know is a key feature of HD.20,23 Be-
cause the progression of neuronal atrophy beyond the caudate
in preHD and manifest HD is fairly slow, analysis using longer
time intervals and a wider range of disease stages would be
useful to further establish the relationship between NfL and
neurodegeneration. Application of these techniques in other
disease cohorts will help us to understand the wider role of
NfL in the neurodegenerative process. Furthermore, this
study is limited because the analysis was performed on a group
of HD gene expansion carriers across a range of premanifest
and manifest stages. This provides more power to detect
eﬀects; however, further analyses within subgroups could
provide detailed information on diﬀerent stages of the disease.
Finally, because of individual diﬀerences among participants,
Figure 4 Significant associations between baseline NfL and change in GM and WM volume after adjustment for CAG
Statistically significant negative associations between baseline NfL and longitudinal change in (A) GM volume and (B)WMvolume, after additional adjustment
for CAG repeat length and the interaction between age and CAG repeat length. All analyseswere adjusted for age, sex, study site, and total intracranial volume
corrected at p < 0.05 family-wise error and are displayed on a study-specific template. GM = gray matter; NfL = neurofilament light; WM = white matter.
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our ﬁndings cannot be applied meaningfully to individual HD
mutation carriers or for clinical decision-making.
We provide further evidence supporting the use of NfL as
a prognostic marker of progression of neuronal damage in
both HD and other neurodegenerative diseases. NfL appears
to be a signiﬁcant indicator of subsequent widespread brain
changes extending beyond the striatum, particularly within
the WM. The ability to measure NfL from plasma provides an
easily accessible biomarker that has close links to the un-
derlying pathology of HD and shows promise as a dynamic
marker of ongoing neuronal change.
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How are plasma levels of neuroﬁlament light (NfL) protein
related to progressive regional atrophy in people carrying the
Huntington disease (HD) gene expansion?
Summary answer
Elevated plasma NfL levels predict occipital gray matter
(GM) atrophy and widespread white matter (WM) volume
reductions.
What is known and what this paper adds
Plasma NfL levels are a biomarker for HD-related deﬁcits and
overall disease progression. This study clariﬁes the speciﬁc
regional atrophy patterns that plasma NfL levels can predict.
Participants and setting
This study retrospectively analyzed data for 243 people car-
rying the HD gene expansion. This included 120 patients with
premanifest HD and 123 with manifest HD. All were partic-
ipants in the TRACK-HD study conducted in London, Lei-
den, Paris, and Vancouver from 2008 to 2011.
Design, size, and duration
Plasma NfL levels were quantiﬁed with an ultrasensitive
single-molecule array method. All patients underwent MRI
assessments of GM and WM volumes. Cross-sectional and
longitudinal voxel-based morphometry were used to analyze
regional volume changes over the 3-year study period.
Primary outcomes
The primary outcomes were associations between plasmaNfL
levels and longitudinal changes in regional GM and WM
volumes.
Main results and the role of chance
After adjustments for gene expansion lengths and age × gene
expansion length interactions, elevated baseline plasma NfL
levels were associated with bilaterally reduced baseline cau-
date nucleus and putamen volumes. Elevated baseline plasma
NfL levels were also associated with widespread longitudinal
WM volume reductions and with longitudinal GM volume
reductions within the inferior and lateral occipital cortices and
small regions of the inferior frontal and superior temporal
gyri.
Bias, confounding, and other reasons
for caution
The study follow-up length might not have been long enough
to fully characterize the relationship between plasma NfL
levels and neurodegeneration.
Generalizability to other populations
Interindividual variation prevents these results from being
used in clinical decision-making for individual patients. Fur-
ther studies within the premanifest and manifest HD sub-
groups are needed to fully understand the clinical importance
of plasma NfL levels. These results support the utility of
plasma NfL as a biomarker that predicts brain atrophy rele-
vant to neurodegeneration.
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